KA/EN
Register
Medicines reference
Search
Search
Active substance

Dexmedetomidine

Favourites

Alpha-2 adrenoceptor agonist. Registered in Georgia: 2 veterinary products. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Dexmedetomidine
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.125–0.375 mg/m² (BSA) Dog Premedication Intravenous / Intramuscular once, 20 minutes before induction
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexdomitor 0.5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
0.375 mg/m² (BSA) Dog Sedation Intravenous single dose; do not repeat
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexdomitor 0.5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
0.5 mg/m² (BSA) Dog Sedation Intramuscular single dose; do not repeat
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexdomitor 0.5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
0.3 mg/m² (BSA) Dog Deep Sedation and Analgesia with Butorphanol
Sedation
 Intramuscular once with butorphanol 0.1 mg/kg
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexdomitor 0.5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
40 mcg/kg Cat Premedication Intramuscular once; induce anaesthesia 10 minutes later
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexdomitor 0.5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
40 mcg/kg Cat Sedation Intramuscular single dose; do not repeat
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Dexdomitor 0.5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use dexmedetomidine in dogs or cats with cardiovascular disease.
    Sources: FDA
  • Critical
    Do not use dexmedetomidine in animals with clinically important bradyarrhythmia. It can cause profound sinus bradycardia, first- or second-degree atrioventricular block, and sinus arrest.
  • Critical
    Do not use DEXDOMITOR in dogs or cats with... respiratory disorders
    Sources: FDA
  • Critical
    Do not use dexmedetomidine in dogs or cats with hepatic disease because reduced hepatic blood flow or metabolism may prolong and intensify its effects.
    Sources: FDA
  • Critical
    Do not use DEXDOMITOR in dogs or cats with... liver or kidney diseases
    Sources: FDA
  • Critical
    Known hypersensitivity to dexmedetomidine or any excipient, including methyl- or propyl parahydroxybenzoate, is a contraindication.
  • Warning
    Dexmedetomidine is not recommended during pregnancy because safety in the target species has not been established.
  • Warning
    Dexmedetomidine is not recommended during lactation because safety in the target species has not been established.
    Sources: Dexdomitor SPC
  • Caution
    Do not use this anaesthetic product in animals with severe systemic disease, shock, profound debilitation, moribund status, or severe stress from extreme temperature or fatigue. It is not intended for repeated injections.
    Sources: FDA
  • Caution
    Dexmedetomidine has not been studied in puppies younger than 16 weeks or kittens younger than 12 weeks. Use cautiously in elderly animals.

Known Drug Interactions

  • Minor warning Dexmedetomidine + Acepromazine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Dexmedetomidine + Atropine
    Use anticholinergic drugs cautiously with dexmedetomidine because marked cardiovascular effects may occur.
    Recommendation: Do not administer together routinely; manage bradycardia individually with monitoring.
    Sources: Dexdomitor SPC · FDA
  • Minor warning Buprenorphine + Dexmedetomidine
    Centrally acting drugs, including tranquillisers, sedatives, and hypnotics, can increase buprenorphine-induced drowsiness. Combined use with sedatives can also increase depression of heart rate and respiration.
    Recommendation: Reduce the sedative dose during premedication; monitor heart rate and respiration.
  • Minor warning Butorphanol + Dexmedetomidine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Ketamine + Dexmedetomidine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Propofol + Dexmedetomidine
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Methadone + Dexmedetomidine
    Methadone can potentiate analgesics, central nervous system depressants, and drugs that cause respiratory depression. Lower doses may be needed when these medicines are combined.
    Recommendation: Reduce doses when used in combination; monitor heart rate and respiration.
    Sources: Comfortan SPC
  • Minor warning Dexmedetomidine + Diazepam
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
  • Minor warning Dexmedetomidine + Glycopyrrolate
    Use anticholinergic drugs cautiously with dexmedetomidine because marked cardiovascular effects may occur.
    Recommendation: Do not administer together routinely; manage bradycardia individually with monitoring.
    Sources: Dexdomitor SPC · FDA
  • Minor warning Dexmedetomidine + Midazolam
    Other central nervous system depressants can potentiate dexmedetomidine; adjust the dose appropriately when they are used together.
    Recommendation: to effect
    Sources: Dexdomitor SPC
Latin name
Dexmedetomidine
Georgian name
დექსმედეტომიდინი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
2 of 2 forms
Products
Dexdomitor, Dexivet
Human medicines in Georgia
Dekstomid, Dexdor, Kvanadex, Prexodin
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Dexdomitor, Solution

Dexmedetomidine hydrochloride 0.5 mg/ml, solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full canine label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures; deep sedation with butorphanol; premedication; and CRI during inhalation anaesthesia
8.3/10
Very good
vetman assessment

Dexdomitor

Dexmedetomidine hydrochloride 0.5 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeDog · Full canine label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures; deep sedation with butorphanol; premedication; and CRI during inhalation anaesthesia · IV,IM
Care settingMonitored veterinary sedation and anaesthesia, with cardiorespiratory and temperature monitoring, oxygen and ventilation support available
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 92-11 · Verified on 18 Oct 2026

A very well documented, reversible alpha-2 sedative-analgesic with broad peri-anaesthetic utility in appropriately selected dogs. Its value depends on disciplined cardiovascular monitoring and exact dosing rather than routine use in compromised patients.

Regulatory and scientific credibility9.5/10

The exact product is registered in Georgia and has current, detailed VMD and FDA labels, extensive regulator-reviewed field data and transparent species-specific dosing.

Clinical efficacy8.5/10

Regulator field studies, independent trials and a 13-study meta-analysis support reliable sedation, analgesia and anaesthetic-sparing effects; the expanded CRI role is useful but supported by a narrower and protocol-dependent evidence base.

Safety and tolerability7.0/10

Safety is unusually well characterised, but clinically important bradycardia, arrhythmia, blood-pressure change, respiratory depression and hypothermia require patient selection and active monitoring.

Clinical practicality8.0/10

IV or IM use, predictable onset, labelled combinations and atipamezole reversal are practical in anaesthesia practice; body-surface-area dosing, very small volumes and CRI dilution demand precision.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in animals with cardiovascular disorders, severe systemic disease, a moribund state or hypersensitivity to the product.
  • Monitor cardiac and respiratory function and body temperature frequently. Keep the patient warm, protect the cornea and have oxygen and manual or mechanical ventilation available when the protocol warrants it.
  • Other CNS depressants potentiate dexmedetomidine and require dose adjustment. Use anticholinergics cautiously; concurrent or subsequent administration can worsen hypertension, tachycardia or arrhythmia.
  • Safety during pregnancy or lactation is not established and use is not recommended. Safety in breeding males is also not established.
  • The injectable bolus is not intended for repeat injections. Calculate small volumes accurately; CRI use requires exact dilution, a syringe or infusion pump and an adjusted total fluid rate.
  • Use in puppies younger than 16 weeks has not been studied.
  • Bradycardia and mucous-membrane colour changes are very common; arrhythmia is common, and blood-pressure change, heart block, pulmonary oedema or respiratory depression may occur.
Assessment sources
  1. VMD SPC 20262026
  2. FDA 20222022
  3. Dog dexmedetomidine meta-analysis2021
  4. Dog dexmedetomidine-butorphanol trial2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full feline label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures; premedication; and CRI during inhalation anaesthesia
8.1/10
Very good
vetman assessment

Dexdomitor

Dexmedetomidine hydrochloride 0.5 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeCat · Full feline label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures; premedication; and CRI during inhalation anaesthesia · IV,IM
Care settingMonitored veterinary sedation and anaesthesia, with active warming, eye protection, cardiorespiratory monitoring, oxygen and ventilation support available
vetman score 8.1/10 Very good
Evidence confidence: Medium Georgia: Yes, veterinary · № 92-11 · Verified on 18 Oct 2026

A strong, reversible feline sedative-analgesic with useful procedural and peri-anaesthetic roles. The evidence is convincing, but the frequency of predictable cardiovascular effects and emesis makes monitoring and protocol discipline central to its safe value.

Regulatory and scientific credibility9.5/10

The exact product is registered in Georgia and has current, detailed VMD and FDA labels with substantial feline field-safety and efficacy data.

Clinical efficacy8.5/10

A blinded multicentre trial and regulator field studies support rapid, clinically useful sedation and analgesia, anaesthetic dose-sparing and effective reversal; CRI evidence is less extensive than the single-dose evidence.

Safety and tolerability6.5/10

The benefit-risk is acceptable in healthy selected cats, but vomiting, bradycardia, arrhythmia and heart block are very common and hypothermia, reduced oxygenation or apnoea can occur, especially around ketamine protocols.

Clinical practicality8.0/10

A single IM dose and a specific antagonist make the regimen workable, but small-volume accuracy, active warming, corneal protection and ketamine-specific timing require an equipped clinic.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in animals with cardiovascular disorders, severe systemic disease, a moribund state or hypersensitivity to the product.
  • Monitor cardiac and respiratory function and body temperature frequently. Keep the patient warm, protect the cornea and have oxygen and manual or mechanical ventilation available when the protocol warrants it.
  • Other CNS depressants potentiate dexmedetomidine and require dose adjustment. Use anticholinergics cautiously; concurrent or subsequent administration can worsen hypertension, tachycardia or arrhythmia.
  • Safety during pregnancy or lactation is not established and use is not recommended. Safety in breeding males is also not established.
  • The injectable bolus is not intended for repeat injections. Calculate small volumes accurately; CRI use requires exact dilution, a syringe or infusion pump and an adjusted total fluid rate.
  • Use in kittens younger than 12 weeks has not been studied.
  • Vomiting, bradycardia, arrhythmia and heart block are very common. Hypothermia, decreased oxygenation and apnoea can occur; ketamine combinations require ventilation readiness and correct reversal timing.
Assessment sources
  1. VMD SPC 20262026
  2. FDA 20222022
  3. Feline dexmedetomidine-atipamezole trial2006
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dexmedetomidine0.5 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular
Manufacturer
Orion Corporation · Finland
Manufacturer (register)
Orion Pharma Animal Health, Finland
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 243, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: დექსდომიტორი
№ 92-11
Verified on: 18 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-267
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Dexivet 0.5 mg/ml, Solution

dexmedetomidine hydrochloride 0.5 mg/ml, solution for injection for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full canine label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures; deep sedation with butorphanol; and premedication before general anaesthesia
8.0/10
Very good
vetman assessment

Dexivet

0.5 mg/ml, dexmedetomidine hydrochloride 0.5 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeDog · Full canine label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures; deep sedation with butorphanol; and premedication before general anaesthesia · IV,IM
Care settingMonitored veterinary sedation and anaesthesia with cardiorespiratory and temperature monitoring and reversal capability
vetman score 8.0/10 Very good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 18 Oct 2026

A transparent, authorised dexmedetomidine generic that offers the established canine sedation and premedication benefits with the same need for cardiovascular monitoring and exact dosing as the reference formulation.

Regulatory and scientific credibility8.5/10

The exact 0.5 mg/ml product is registered in Georgia and valid in the EU network under a transparent generic authorisation with a regulator-hosted exact-product SPC.

Clinical efficacy8.5/10

The authorised product matches the established dexmedetomidine concentration and regimen; regulator data, independent trials and meta-analysis support the class effects without evidence that a properly authorised generic should be clinically discounted.

Safety and tolerability7.0/10

The expected safety profile is well defined but includes clinically important bradycardia, arrhythmia, blood-pressure change, respiratory depression and hypothermia requiring selection and monitoring.

Clinical practicality8.0/10

IV or IM administration and atipamezole reversal fit routine anaesthesia workflows, although body-surface-area dosing and small injectable volumes require accurate calculation and syringes.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in animals with cardiovascular disorders, severe systemic disease, a moribund state or hypersensitivity to the product.
  • Monitor cardiac and respiratory function and body temperature frequently. Keep the patient warm, protect the cornea and have oxygen and manual or mechanical ventilation available when the protocol warrants it.
  • Other CNS depressants potentiate dexmedetomidine and require dose adjustment. Use anticholinergics cautiously; concurrent or subsequent administration can worsen hypertension, tachycardia or arrhythmia.
  • Safety during pregnancy or lactation is not established and use is not recommended. Safety in breeding males is also not established.
  • The injectable bolus is not intended for repeat injections. Calculate small volumes accurately; CRI use requires exact dilution, a syringe or infusion pump and an adjusted total fluid rate.
  • Use in puppies younger than 16 weeks has not been studied.
  • Bradycardia and mucous-membrane colour changes are very common; arrhythmia is common, and blood-pressure change, heart block, pulmonary oedema or respiratory depression may occur.
Assessment sources
  1. UPD SPC 20252025
  2. Dog dexmedetomidine meta-analysis2021
  3. Dog dexmedetomidine-butorphanol trial2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full feline label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures and premedication before general anaesthesia
7.9/10
Good
vetman assessment

Dexivet

0.5 mg/ml, dexmedetomidine hydrochloride 0.5 mg/ml, solution for injection for dogs and cats
Assessed clinical scopeCat · Full feline label: restraint, sedation and analgesia for non-invasive mildly to moderately painful procedures and premedication before general anaesthesia · Intramuscular
Care settingMonitored veterinary sedation and anaesthesia with warming, eye protection, cardiorespiratory monitoring and reversal capability
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 18 Oct 2026

A credible authorised generic for feline procedural sedation and premedication. Its efficacy is well supported by applicable dexmedetomidine evidence, while safe use still depends on active monitoring and management of common predictable alpha-2 effects.

Regulatory and scientific credibility8.5/10

The exact 0.5 mg/ml product is registered in Georgia and valid in the EU network under a transparent generic authorisation with a regulator-hosted exact-product SPC.

Clinical efficacy8.5/10

The exact authorised product uses the established feline dexmedetomidine regimen, while blinded clinical and regulator field studies support procedural sedation, analgesia, anaesthetic dose-sparing and reversal for this concentration.

Safety and tolerability6.5/10

Expected alpha-2 adverse effects are well characterised: vomiting, bradycardia, arrhythmia and heart block are prominent, with possible hypothermia, reduced oxygenation and apnoea.

Clinical practicality8.0/10

A single IM dose and atipamezole reversal are workable in practice, but small-volume accuracy, warming, corneal protection and ketamine-aware recovery require an equipped clinic.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in animals with cardiovascular disorders, severe systemic disease, a moribund state or hypersensitivity to the product.
  • Monitor cardiac and respiratory function and body temperature frequently. Keep the patient warm, protect the cornea and have oxygen and manual or mechanical ventilation available when the protocol warrants it.
  • Other CNS depressants potentiate dexmedetomidine and require dose adjustment. Use anticholinergics cautiously; concurrent or subsequent administration can worsen hypertension, tachycardia or arrhythmia.
  • Safety during pregnancy or lactation is not established and use is not recommended. Safety in breeding males is also not established.
  • The injectable bolus is not intended for repeat injections. Calculate small volumes accurately; CRI use requires exact dilution, a syringe or infusion pump and an adjusted total fluid rate.
  • Use in kittens younger than 12 weeks has not been studied.
  • Vomiting, bradycardia, arrhythmia and heart block are very common. Hypothermia, decreased oxygenation and apnoea can occur; ketamine combinations require ventilation readiness and correct reversal timing.
Assessment sources
  1. UPD SPC 20252025
  2. Feline dexmedetomidine-atipamezole trial2006
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Dexmedetomidine0.5 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular
Manufacturer
Bioveta · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: დექსივეტი 0.5 მგ/მლ საინექციო ხსნარი
Verified on: 18 Oct 2026
 EU Yes, veterinary
№ 96/012/23-C
Verified on: 18 Oct 2026
 UK No
Verified on: 18 Oct 2026
 US No
Verified on: 18 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗